Trv Gp Vi LLC Invests $72.19 Million in Septerna, Inc. (NASDAQ:SEPN)

TRV GP VI LLC bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 3,152,456 shares of the company's stock, valued at approximately $72,191,000. Septerna accounts for approximately 61.7% of TRV GP VI LLC's investment portfolio, making the stock its largest holding. TRV GP VI LLC owned 7.10% of Septerna as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. New York State Common Retirement Fund purchased a new position in Septerna during the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new position in shares of Septerna during the fourth quarter valued at approximately $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna in the 4th quarter worth approximately $45,000. PNC Financial Services Group Inc. purchased a new stake in shares of Septerna in the 4th quarter worth approximately $61,000. Finally, SG Americas Securities LLC bought a new position in Septerna during the 4th quarter valued at approximately $185,000.

Septerna Stock Performance

NASDAQ:SEPN traded up $0.10 during mid-day trading on Tuesday, reaching $5.97. The company's stock had a trading volume of 190,514 shares, compared to its average volume of 434,484. The firm's fifty day simple moving average is $6.23. Septerna, Inc. has a 12-month low of $4.17 and a 12-month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, research analysts predict that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insider Buying and Selling at Septerna

In other Septerna news, Director Alan Ezekowitz acquired 7,491 shares of the stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the purchase, the director now directly owns 24,911 shares of the company's stock, valued at approximately $158,184.85. This trade represents a 43.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Gil M. Labrucherie bought 5,000 shares of Septerna stock in a transaction on Friday, February 21st. The shares were acquired at an average cost of $5.85 per share, with a total value of $29,250.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares of the company's stock, valued at $175,500. The trade was a 20.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 74,346 shares of company stock valued at $439,670.

Wall Street Analyst Weigh In

SEPN has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company dropped their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, March 28th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.